FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384920203> ?p ?o ?g. }

• W4384920203 endingPage "e18498" @default.
• W4384920203 startingPage "e18498" @default.
• W4384920203 abstract "Endocrine resistance hormone receptor-positive (HR+) advanced breast cancer (ABC) is generally insensitive to immunecheckpoint inhibitors (ICIs). This study sought to determine whether PI3Kδ inhibitor could enhance the sensitivity of endocrine resistance HR + advanced BC to ICIs by reducing immune evasion.Patient-derived HR + ABC xenografts were implanted into immune-humanized NSG mice and subsequently treated with YY20394 (PI3Kδ inhibitor) and camrelizumab. The mice were monitored for tumor progression, biochemical blood indicators, and peripheral blood T-cell subsets. The xenografted tumors were collected at the end of the treatment cycle and subjected to HE staining, immunohistochemistry and protein phosphorylation analysis. Besides, the xenografted tumors were also used to isolate primary breast cancer cells (BCCs) and regulatory T-cells (Tregs), which were subsequently used to evaluate drug sensitivity in vitro.The humanized PDX model showed a favorable initial treatment response to camrelizumab combined with YY20394 and manageable toxicity. YY20394 plus camrelizumab showed a strong inhibitory effect on HR + BC in vivo mediated by suppression of Treg activity and an increased proportion of CD8+ T cells. Mice bearing tumors treated with YY20394 and camrelizumab had less invasion, mitotic figures, and ki67 expression, while having higher IL-12 expression compared with other groups. Mechanistically, YY20394 only effectively inhibited the PI3K pathway and proliferation activity in Tregs but not in BCCs.Our study suggests PI3Kδ inhibitor could the enhance the efficacy of ICIs in HR + BC PDX models by combating immune suppression and provides a feasible approach that may overcome the resistance of ICIs in HR + BC patients." @default.
• W4384920203 created "2023-07-21" @default.
• W4384920203 creator A5011509895 @default.
• W4384920203 creator A5016136933 @default.
• W4384920203 creator A5030725597 @default.
• W4384920203 creator A5031524996 @default.
• W4384920203 creator A5041623170 @default.
• W4384920203 creator A5043241104 @default.
• W4384920203 creator A5044845459 @default.
• W4384920203 creator A5049007476 @default.
• W4384920203 creator A5063187243 @default.
• W4384920203 creator A5083484483 @default.
• W4384920203 creator A5089431028 @default.
• W4384920203 creator A5089669072 @default.
• W4384920203 date "2023-08-01" @default.
• W4384920203 modified "2023-10-18" @default.
• W4384920203 title "Synergistic efficacy of PI3Kδ inhibitor with anti-PD-1 mAbs in immune-humanized PDX model of endocrine resistance hormone receptor-positive advanced breast cancer" @default.
• W4384920203 cites W1980040544 @default.
• W4384920203 cites W2012228539 @default.
• W4384920203 cites W2034270173 @default.
• W4384920203 cites W2095861825 @default.
• W4384920203 cites W2112648444 @default.
• W4384920203 cites W2117692326 @default.
• W4384920203 cites W2221588520 @default.
• W4384920203 cites W2277613139 @default.
• W4384920203 cites W2290349987 @default.
• W4384920203 cites W2346465624 @default.
• W4384920203 cites W2573719758 @default.
• W4384920203 cites W2613492884 @default.
• W4384920203 cites W2619858681 @default.
• W4384920203 cites W2625574648 @default.
• W4384920203 cites W2625852679 @default.
• W4384920203 cites W2744067212 @default.
• W4384920203 cites W2744377419 @default.
• W4384920203 cites W2771978163 @default.
• W4384920203 cites W2790574591 @default.
• W4384920203 cites W2791308824 @default.
• W4384920203 cites W2806773230 @default.
• W4384920203 cites W2917721259 @default.
• W4384920203 cites W2945564879 @default.
• W4384920203 cites W3002154893 @default.
• W4384920203 cites W3024073709 @default.
• W4384920203 cites W3030487289 @default.
• W4384920203 cites W3045706461 @default.
• W4384920203 cites W3111468108 @default.
• W4384920203 cites W3162972203 @default.
• W4384920203 cites W3170960533 @default.
• W4384920203 cites W3173705400 @default.
• W4384920203 cites W3184322803 @default.
• W4384920203 cites W4200406720 @default.
• W4384920203 cites W4200584507 @default.
• W4384920203 cites W4214718007 @default.
• W4384920203 cites W4229001659 @default.
• W4384920203 doi "https://doi.org/10.1016/j.heliyon.2023.e18498" @default.
• W4384920203 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37533997" @default.
• W4384920203 hasPublicationYear "2023" @default.
• W4384920203 type Work @default.
• W4384920203 citedByCount "0" @default.
• W4384920203 crossrefType "journal-article" @default.
• W4384920203 hasAuthorship W4384920203A5011509895 @default.
• W4384920203 hasAuthorship W4384920203A5016136933 @default.
• W4384920203 hasAuthorship W4384920203A5030725597 @default.
• W4384920203 hasAuthorship W4384920203A5031524996 @default.
• W4384920203 hasAuthorship W4384920203A5041623170 @default.
• W4384920203 hasAuthorship W4384920203A5043241104 @default.
• W4384920203 hasAuthorship W4384920203A5044845459 @default.
• W4384920203 hasAuthorship W4384920203A5049007476 @default.
• W4384920203 hasAuthorship W4384920203A5063187243 @default.
• W4384920203 hasAuthorship W4384920203A5083484483 @default.
• W4384920203 hasAuthorship W4384920203A5089431028 @default.
• W4384920203 hasAuthorship W4384920203A5089669072 @default.
• W4384920203 hasBestOaLocation W43849202031 @default.
• W4384920203 hasConcept C121608353 @default.
• W4384920203 hasConcept C126322002 @default.
• W4384920203 hasConcept C167672396 @default.
• W4384920203 hasConcept C203014093 @default.
• W4384920203 hasConcept C2776156784 @default.
• W4384920203 hasConcept C2777701055 @default.
• W4384920203 hasConcept C502942594 @default.
• W4384920203 hasConcept C530470458 @default.
• W4384920203 hasConcept C71924100 @default.
• W4384920203 hasConcept C8891405 @default.
• W4384920203 hasConcept C98274493 @default.
• W4384920203 hasConceptScore W4384920203C121608353 @default.
• W4384920203 hasConceptScore W4384920203C126322002 @default.
• W4384920203 hasConceptScore W4384920203C167672396 @default.
• W4384920203 hasConceptScore W4384920203C203014093 @default.
• W4384920203 hasConceptScore W4384920203C2776156784 @default.
• W4384920203 hasConceptScore W4384920203C2777701055 @default.
• W4384920203 hasConceptScore W4384920203C502942594 @default.
• W4384920203 hasConceptScore W4384920203C530470458 @default.
• W4384920203 hasConceptScore W4384920203C71924100 @default.
• W4384920203 hasConceptScore W4384920203C8891405 @default.
• W4384920203 hasConceptScore W4384920203C98274493 @default.
• W4384920203 hasFunder F4320312270 @default.
• W4384920203 hasIssue "8" @default.
• W4384920203 hasLocation W43849202031 @default.
• W4384920203 hasLocation W43849202032 @default.

• next